Sanofi $SNY Shares Sold by Alyeska Investment Group L.P.

Key Points

• Alyeska Investment Group L.P. has drastically reduced its stake in Sanofi by 85.9%, now owning 141,189 shares after selling 861,443 shares in the first quarter.
• Sanofi's quarterly earnings reported a net margin of 21.47%, with a revenue of $11.34 billion, surpassing analysts' expectations of $9.91 billion.
• Equities analysts are optimistic on Sanofi, with recent upgrades including ratings from JPMorgan and Deutsche Bank, indicating an overall average rating of "Buy".

Alyeska Investment Group L.P. decreased its position in Sanofi (NASDAQ:SNY - Free Report) by 85.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 141,189 shares of the company's stock after selling 861,443 shares during the quarter. Alyeska Investment Group L.P.'s holdings in Sanofi were worth $7,830,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Sanofi by 124.0% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company's stock valued at $1,344,000 after purchasing an additional 13,358 shares in the last quarter. Axxcess Wealth Management LLC grew its stake in shares of Sanofi by 130.5% during the first quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company's stock worth $568,000 after purchasing an additional 5,794 shares in the last quarter. Ballentine Partners LLC increased its holdings in Sanofi by 68.7% in the first quarter. Ballentine Partners LLC now owns 26,063 shares of the company's stock valued at $1,445,000 after buying an additional 10,617 shares during the last quarter. Sowell Financial Services LLC acquired a new stake in Sanofi in the first quarter valued at $328,000. Finally, Farther Finance Advisors LLC lifted its holdings in Sanofi by 66.2% during the 1st quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company's stock worth $338,000 after buying an additional 2,476 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on SNY shares. Guggenheim reiterated a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "hold" rating to a "buy" rating in a research note on Tuesday, September 2nd. JPMorgan Chase & Co. upgraded shares of Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Barclays reissued an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Finally, Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $62.67.

Sanofi Stock Performance

SNY traded up $0.49 on Thursday, hitting $47.65. 2,340,983 shares of the company traded hands, compared to its average volume of 2,656,988. Sanofi has a 12-month low of $44.73 and a 12-month high of $60.12. The company has a 50 day moving average of $48.68 and a 200-day moving average of $51.21. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $117.01 billion, a PE ratio of 11.45, a PEG ratio of 1.12 and a beta of 0.51.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm had revenue of $11.34 billion during the quarter, compared to analysts' expectations of $9.91 billion. During the same quarter last year, the business earned $1.73 earnings per share. The business's quarterly revenue was down 7.0% on a year-over-year basis. Sell-side analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.